Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea (OSCILLOREVERS)

Hopital Foch

Status

Terminated

Conditions

COPD

Treatments

Other: COPD

Study type

Interventional

Funder types

Other

Identifiers

NCT02928744

2011/43

2011-A00964-37 (Other Identifier)

Details and patient eligibility

About

Limitation of expiratory flows is considered as the main determiner of dynamic distension and dyspnoea in chronic obstructive pulmonary disease (COPD). The analysis of proximal and distal resistances should allow to better appreciate the functional impact.

This study should also allow to specify the best parameters in respiratory functional explorations useful for the follow-up in COPD and to specify the relevance of functional indications other than the forced expiration volume at 1 second (FEV1) or the functional residual capacity (FRC) to estimate in a more relevant way the clinical improve with the increase of the therapeutic load (increase of posology, association of two bronchodilatators, addition of an anti-inflammatory drug, thus etc...) at already handled patients suffering from a persistent dyspnoea insufficiently relieved.

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

COPD with dyspnoea with Medical Research Council scale (MRC) >1,
No exacerbation for 6 weeks
No bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours before the respiratory evaluation and the test of reversibility.
Patient under current treatment (ß2 long-acting agonist (LABA) or anticholinergic long-acting (LLAMA(LAMA)) or LABA-corticoid association inhaled (CSI), or triples LABA-CSI-LAMA association) stable for at least 4 weeks, and taken for at least the 1 hour the day of the visit
Having given a written consent

Exclusion criteria

Patient Under 18
Other respiratory illness
Clinically significant left cardiac failure
Obesity with BMI > 35 kg / m2)
Unable to perform respiratory evaluations
Contraindication to the salbutamol or to the ipratropium bromide or to one of its components
Pregnant or breast-feeding woman
Unable to agree
No social security scheme